GlaxoSmithKline plc Could Be Worth 1,880p

Gains of 20% or more (including dividends) could be on offer for investors in GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical stocks such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are viewed a lot differently by investors these days than they were 15 years or so ago.

Back then, they were considered high-growth stocks and attracted risk-takers who wanted to see their investment multiply, albeit with the risk of the company crashing and burning due to unfavourable FDA decisions or negative drug trials.

Today, pharmaceuticals are viewed as much more stable, high yield and limited growth companies. Indeed, they no longer enjoy the kind of earnings growth rates that they used to, with GlaxoSmithKline, for instance, forecast to deliver earnings per share (EPS) growth of 7% over the next year.

This may seem a little disappointing. But when you consider that GlaxoSmithKline currently trades on a price to earnings (P/E) ratio of 13.4, it translates into a price to earnings growth (PEG) ratio of 1.92.

Of course, this in itself may not seem so exciting, with a PEG ratio of 1 being seen as the ‘sweet spot’ of growth investing. However, with the FTSE 100 currently on a PEG ratio of closer to 2.5, as a result of sluggish growth prospects, and a P/E of 15.8, GlaxoSmithKline starts to look relatively good value.

In fact, if GlaxoSmithKline were to trade on a PEG of somewhere between its current figure and that of the FTSE 100 (say 2.2), it would mean that shares would be priced at around 1880p. This is just under 15% higher than the current share price and would, nevertheless, still mean that GlaxoSmithKline trades on a lower PEG than the wider market.

In my view, this share price increase is entirely possible, since GlaxoSmithKline continues to benefit from far higher barriers to entry than the run-of-the-mill FTSE 100 company. Although patents eventually expire, GlaxoSmithKline continues to enjoy a strong pipeline of drugs and this looks set to enable the business to maintain margins and deliver the earnings growth figures that the market is anticipating over the medium to long term.

Furthermore, with shares currently offering a yield of 4.8%, total profit of 20%+ could be on the cards for more patient investors.

So, GlaxoSmithKline’s shares still appear to be good value based on a PEG ratio of 1.92 — especially when it’s compared to the market, and when the high entry-barriers that GlaxoSmithKline benefits from are taken into account. A gain of 15% over the medium to long term looks to be achievable, with a dividend yield of 4.8% meaning total returns could exceed 20%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »